A Phase 2 interventional study of CHF 5259 and Placebo in COPD and Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 112 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-06-15.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 4 that started in 2017, is one of 19 in phase 2, and was the 58th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 733 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A.: 5 open now, 5 under way, none of them phase 3. Of 62 finished, 7 (11%) have results posted.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 12th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2017, is one of 15 in phase 2, and was the 39th registered.
Chiesi Farmaceutici S.p.A.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2004.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 68 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development in the target subject population.
This is a phase II, multicenter, randomized, double-blind, placebo and active controlled dose-ranging 6-arm parallel group study to identify the optimal dose of CHF 5259 pMDI (pressurized metered dose inhaler) with respect to lung function as well as other clinical efficacy and safety outcomes.
After a 2 week run-in period under rescue albuterol and background inhaled corticosteroid (ICS) as needed, patients were randomized to one of the 6 study treatment groups. Following randomization, subjects were assessed after 3 weeks and 6 weeks of study treatment at the study center. A follow-up phone was performed a week after the last visit.
During the study, daily symptoms, rescue and background medication use and compliance with the study drug were recorded in a subject diary. Treatment-Emergent Adverse Events (TEAEs) were assessed and recorded throughout the study. At screening and subsequent visits, subjects underwent physical and vital signs examinations, spirometry measurements, and 12-lead electrocardiogram (ECG). Symptoms and chronic obstructive pulmonary disease (COPD) health status were assessed through validated questionnaires. Routine hematology, blood chemistry, and pregnancy testing were performed before enrollment and at end of study. 24-hour (24-H) digital recording of ECGs (Holter) was performed before and after the first dose and just before the last dose of study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose \[TDD\] of CHF 5259 12.5 μg)
Drug: CHF 5259
CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
Drug: CHF 5259
CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
Drug: CHF 5259
CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
Drug: CHF 5259
Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
Drug: Placebo
Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
Drug: Tiotropium Bromide 18 µg Inhalation Capsule
Dose Response: Test one of four different doses of CHF 5259
Placebo Control
Active Control
Also known as: SPIRIVA® HANDIHALER®
Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6
Change from baseline in FEV1 AUC(0-12h), normalized by time, at the end of treatment (Week 6). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;
Time frame: Baseline, Week 6
Change From Baseline in FEV1 AUC(0-12h) Normalized by Time on Day 1
Change from baseline in FEV1 AUC(0-12h), normalized by time, on Day 1. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;
Time frame: Baseline, Day 1
Change From Baseline in FEV1 AUC(0-4h) Normalized by Time on Day 1 and at Week 6
Change from baseline in FEV1 AUC(0-4h), normalized by time on Day 1 of treatment (Week 0). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 and at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-4h)=Mean FEV1 after inhalation, measured at prespecified times for up to 4-h observation period (0-4h), normalized by time;
Time frame: Baseline, Day 1, Week 6
Change From Baseline in FEV1 Peak(0-4h) at Day 1 and Week 6
Change from baseline in FEV1 peak(0-4h) (L) on Day 1 and at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.
Time frame: Baseline, Day 1, Week 6
Change From Baseline in FVC AUC(0-12h), Normalized by Time on Day 1 and at Week 6
Change from baseline in FVC AUC(0-12h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-12h)=Mean FVC after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;
Time frame: Baseline, Day 1, Week 6
Change From Baseline in FVC AUC(0-4h) Normalized by Time on Day 1 and at Week 6
Change from baseline in FVC AUC(0-4h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-4)=Mean FVC after inhalation, measured at prespecified times for up to 4-h observation period (0-4 h), normalized by time;
Time frame: Baseline, Day 1, Week 6
Change From Baseline in FVC Peak(0-4h) on Day 1 and at Week 6
Change from baseline in FVC peak(0-4h) (L) on Day 1 and at the end of treatment at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.
Time frame: Baseline, Day 1, Week 6
Time to Onset of Action (Change From Baseline in Post-dose FEV1 ≥ 100 mL) on Day 1
Time to onset of action is defined as the time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥100 mL.
Time frame: Day 1
Number of Patients Achieving Onset of Action - Change From Baseline in Post-dose FEV1 ≥100 mL on Day 1
Number of patients achieving onset of action was defined as a change from baseline in post-dose FEV1 ≥100 mL on Day 1. These are the patients who contributed to the results, reported as median and 95% CI for 'time to onset of action' presented in Outcome Measure 8, above.
Time frame: Day 1
Change From Baseline in Pre-dose Morning FEV1 at Week 3 and Week 6
Change from baseline in FEV1 at treatment visit 3 (Week 3) and treatment visit 4 (Week 6) of treatment. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second;
Time frame: Baseline, Week 3, Week 6
Change From Baseline in Pre-Dose Morning Inspiratory Capacity (IC) at Week 3 and Week 6
Change from baseline in IC at treatment Visit 3 (Week 3) and treatment Visit 4 (Week 6). Spirometry was used to measure IC and was performed according to internationally accepted standards. Definitions: Baseline: value of the measurement recorded at 45 mins pre-dose at Visit 2 (Week 0); IC=Inspiratory capacity;
Time frame: Baseline, Week 3, Week 6
Transition Dyspnea Index (TDI) Response (Focal Score ≥1) at Week 3 and Week 6
Number of subjects achieving TDI focal score ≥1, at treatment visit 3 (Week 3) and at treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement); total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;
Time frame: Baseline, Week 3, Week 6
Transition Dyspnea Index (TDI) Focal Score at Week 3 and Week 6
Transitional Dyspnea Index (TDI) focal score at treatment visit 3 (Week 3) and treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement), with a total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;
Time frame: Baseline, Week 3, Week 6
Change From Baseline in Percentage of Rescue Medication-Free Days During Inter-Visit Periods and the Entire Treatment Period
Evaluate the number of rescue medication-free days compared with baseline. Results are shown as percentage (%) of rescue medication-free days; an increased value indicates improvement from baseline. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3, Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0).
Time frame: Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period
Change From Baseline in Average Use of Rescue Medication During Inter-Visit Periods and the Entire Treatment Period
Evaluate the change from baseline in average use of rescue medication (number of puffs/day) during the inter-visit periods and the entire treatment period. Results are shown as number of puffs/day; a decrease (implies improvement) from baseline in average use of rescue medication. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3 (Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0);
Time frame: Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period
Change From Baseline in Average EXACT-Respiratory Symptom (E-RS) Total Score During Inter-Visit Periods and the Entire Treatment Period
Change from baseline in average EXACT-Respiratory Symptom (E-RS) total score during inter-visit periods and the entire treatment period E-RS in COPD uses 11 respiratory symptom items from the 14-item EXAcerbations of COPD tool (EXACT). E-RS total score quantifies respiratory symptom severity on a scale ranging from 0 to 40. Higher E-RS total scores indicate more severe symptoms and a declining total score indicates health improvement. E-RS questionnaire was completed by the patient each evening (e-diary). Definitions: For details on baseline, inter-visit periods, and the entire treatment period, please refer to outcome measure #15.
Time frame: Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period
Vital Signs -- Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
Vital signs -- Systolic blood pressure (SBP), Diastolic blood pressure (DBP) were measured at prespecified times, using a 12-Lead single ECGs were recorded at all study visits (pre-dose at V1 (Week -2) and V3 (Week 3), as well as at pre-dose and 1.5 hours post-dose at Visit 2 (Week 0) and Visit 4 (Week 6). Results are shown by treatment group, as change from baseline (in mmHg) for representative timepoints. Definitions: Baseline=Values recorded pre-dose (Visit 2, Week 0); Day 1=Day of the first dose of randomized study drug (Visit 2, Week 0);
Time frame: Baseline, Day 1, Week 6
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Heart Rate (HR)
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Heart rate (HR) Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5m, +55m, and at +2.5 h.
Time frame: Baseline, Day 1, Week 6
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - PR Interval
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - PR Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
Time frame: Baseline, Day 1, Week 6
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - QRS Interval
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - QRS Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
Time frame: Baseline, Day 1, Week 6
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Fridericia-corrected QT Interval (QTcF)
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Fridericia-corrected QT interval (QTcF). Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
Time frame: Baseline, Day 1, Week 6
24-hour Holter ECG - Prolonged QTcF - Male Subjects
24-hour Holter ECG - Prolonged QTcF - Male subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
Time frame: Baseline, Day 1, Week 6
24-hour Holter ECG - Prolonged QTcF - Female Subjects
24-hour Holter ECG - Prolonged QTcF - Female subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
Time frame: Baseline, Day 1, Week 6
24-hour Holter ECG - Prolonged QTcF - Change From Baseline
24-hour Holter ECG - Prolonged QTcF - Change from baseline. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h. Results are presented as the number of subjects who had a change from baseline in QTcF of: \> 30 msec, \> 60 msec, and no prolongation (by \> 30 msec or \> 60 msec).
Time frame: Baseline, Day 1, Week 6
| Milestone | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Started | 121 | 123 | 122 | 123 | 121 | 123 |
| Completed | 114 | 113 | 110 | 119 | 110 | 116 |
| Not completed | 7 | 10 | 12 | 4 | 11 | 7 |
| Withdrew: Adverse event | 4 | 5 | 6 | 2 | 3 | 5 |
| Withdrew: Withdrawal by subject | 3 | 5 | 2 | 1 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 3 | 1 |
| Withdrew: Randomization error | 0 | 0 | 1 | 0 | 0 | 0 |
Change from baseline in FEV1 AUC(0-12h), normalized by time, at the end of treatment (Week 6). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6 | 0.070 (0.034 to 0.106) | 0.118 (0.082 to 0.155) | 0.153 (0.116 to 0.190) | 0.147 (0.111 to 0.183) | 0.002 (-0.035 to 0.039) | 0.213 (0.177 to 0.250) |
Change from baseline in FEV1 AUC(0-12h), normalized by time, on Day 1. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Change From Baseline in FEV1 AUC(0-12h) Normalized by Time on Day 1 | 0.067 (0.041 to 0.093) | 0.086 (0.060 to 0.111) | 0.135 (0.109 to 0.161) | 0.149 (0.123 to 0.175) | 0.009 (-0.017 to 0.035) | 0.192 (0.166 to 0.218) |
Change from baseline in FEV1 AUC(0-4h), normalized by time on Day 1 of treatment (Week 0). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 and at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-4h)=Mean FEV1 after inhalation, measured at prespecified times for up to 4-h observation period (0-4h), normalized by time;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Day 1 | 0.101 (0.077 to 0.125) | 0.115 (0.091 to 0.139) | 0.173 (0.149 to 0.196) | 0.190 (0.166 to 0.214) | 0.030 (0.006 to 0.053) | 0.194 (0.170 to 0.218) |
| Week 6 | 0.116 (0.078 to 0.154) | 0.157 (0.118 to 0.195) | 0.198 (0.159 to 0.237) | 0.204 (0.167 to 0.242) | 0.024 (-0.015 to 0.062) | 0.253 (0.215 to 0.291) |
Change from baseline in FEV1 peak(0-4h) (L) on Day 1 and at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Day 1 | 0.197 (0.170 to 0.224) | 0.211 (0.183 to 0.238) | 0.260 (0.233 to 0.287) | 0.288 (0.261 to 0.315) | 0.136 (0.109 to 0.163) | 0.299 (0.272 to 0.326) |
| Week 6 | 0.212 (0.171 to 0.253) | 0.255 (0.214 to 0.296) | 0.305 (0.263 to 0.346) | 0.301 (0.260 to 0.341) | 0.143 (0.102 to 0.185) | 0.356 (0.315 to 0.397) |
Change from baseline in FVC AUC(0-12h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-12h)=Mean FVC after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Day 1 | 0.086 (0.039 to 0.133) | 0.133 (0.086 to 0.180) | 0.195 (0.148 to 0.242) | 0.220 (0.173 to 0.267) | 0.011 (-0.036 to 0.058) | 0.305 (0.258 to 0.351) |
| Week 6 | 0.084 (0.026 to 0.142) | 0.145 (0.087 to 0.203) | 0.190 (0.131 to 0.249) | 0.184 (0.127 to 0.241) | -0.029 (-0.087 to 0.030) | 0.298 (0.240 to 0.355) |
Change from baseline in FVC AUC(0-4h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-4)=Mean FVC after inhalation, measured at prespecified times for up to 4-h observation period (0-4 h), normalized by time;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Day 1 | 0.133 (0.087 to 0.179) | 0.192 (0.146 to 0.238) | 0.244 (0.198 to 0.290) | 0.273 (0.227 to 0.319) | 0.036 (-0.010 to 0.082) | 0.311 (0.266 to 0.357) |
| Week 6 | 0.149 (0.089 to 0.210) | 0.203 (0.143 to 0.264) | 0.248 (0.187 to 0.309) | 0.253 (0.194 to 0.313) | 0.000 (-0.062 to 0.061) | 0.353 (0.293 to 0.413) |
Change from baseline in FVC peak(0-4h) (L) on Day 1 and at the end of treatment at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Day 1 | 0.293 (0.241 to 0.345) | 0.372 (0.320 to 0.423) | 0.414 (0.362 to 0.466) | 0.455 (0.403 to 0.506) | 0.213 (0.161 to 0.266) | 0.491 (0.439 to 0.542) |
| Week 6 | 0.322 (0.258 to 0.386) | 0.379 (0.315 to 0.443) | 0.431 (0.366 to 0.495) | 0.427 (0.364 to 0.490) | 0.182 (0.117 to 0.247) | 0.530 (0.467 to 0.594) |
Time to onset of action is defined as the time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥100 mL.
| minutes | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Time to Onset of Action (Change From Baseline in Post-dose FEV1 ≥ 100 mL) on Day 1 | 45.1 (34.5 to 66.2) | 32.6 (30.7 to 45.6) | 29.5 (16.3 to 30.8) | 27.3 (16.5 to 30.5) | 240.1 (179.6 to 361.8) | 28.1 (18.0 to 32.1) |
Number of patients achieving onset of action was defined as a change from baseline in post-dose FEV1 ≥100 mL on Day 1. These are the patients who contributed to the results, reported as median and 95% CI for 'time to onset of action' presented in Outcome Measure 8, above.
| Participants | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Number of Patients Achieving Onset of Action - Change From Baseline in Post-dose FEV1 ≥100 mL on Day 1 | 90 | 103 | 103 | 110 | 74 | 113 |
Change from baseline in FEV1 at treatment visit 3 (Week 3) and treatment visit 4 (Week 6) of treatment. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Week 3 | 0.059 (0.025 to 0.092) | 0.080 (0.047 to 0.114) | 0.122 (0.088 to 0.156) | 0.111 (0.078 to 0.145) | 0.000 (-0.034 to 0.034) | 0.122 (0.089 to 0.156) |
| Week 6 | 0.020 (-0.018 to 0.058) | 0.088 (0.050 to 0.126) | 0.107 (0.068 to 0.145) | 0.130 (0.093 to 0.168) | -0.012 (-0.050 to 0.027) | 0.112 (0.074 to 0.150) |
Change from baseline in IC at treatment Visit 3 (Week 3) and treatment Visit 4 (Week 6). Spirometry was used to measure IC and was performed according to internationally accepted standards. Definitions: Baseline: value of the measurement recorded at 45 mins pre-dose at Visit 2 (Week 0); IC=Inspiratory capacity;
| Litres | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Week 3 | 0.156 (0.090 to 0.222) | 0.137 (0.071 to 0.203) | 0.106 (0.040 to 0.172) | 0.140 (0.074 to 0.205) | 0.047 (-0.020 to 0.113) | 0.090 (0.024 to 0.156) |
| Week 6 | 0.045 (-0.025 to 0.115) | 0.090 (0.021 to 0.160) | 0.136 (0.065 to 0.207) | 0.105 (0.036 to 0.174) | 0.025 (-0.046 to 0.096) | 0.099 (0.029 to 0.169) |
Number of subjects achieving TDI focal score ≥1, at treatment visit 3 (Week 3) and at treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement); total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;
| Participants | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Week 3 Focal Score ≥ 1 | 70 | 78 | 75 | 84 | 67 | 74 |
| Week 6 Focal Score ≥ 1 | 74 | 83 | 82 | 91 | 55 | 80 |
Transitional Dyspnea Index (TDI) focal score at treatment visit 3 (Week 3) and treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement), with a total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;
| score on a scale | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Week 3 | 1.29 (0.82 to 1.75) | 1.55 (1.09 to 2.01) | 1.54 (1.07 to 2.01) | 1.94 (1.47 to 2.40) | 1.14 (0.67 to 1.61) | 1.66 (1.20 to 2.13) |
| Week 6 | 1.65 (1.18 to 2.11) | 2.02 (1.55 to 2.48) | 2.05 (1.58 to 2.52) | 2.55 (2.09 to 3.01) | 1.03 (0.56 to 1.51) | 2.11 (1.65 to 2.58) |
Evaluate the number of rescue medication-free days compared with baseline. Results are shown as percentage (%) of rescue medication-free days; an increased value indicates improvement from baseline. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3, Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0).
| % of of rescue medication-free days | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Inter-visit period 1 | 16.78 (12.02 to 21.54) | 15.67 (10.96 to 20.39) | 15.55 (10.79 to 20.31) | 18.19 (13.44 to 22.94) | 8.90 (4.12 to 13.68) | 13.51 (8.52 to 18.50) |
| Inter-visit period 2 | 13.83 (8.69 to 18.97) | 15.51 (10.40 to 20.62) | 14.03 (8.83 to 19.23) | 18.15 (13.04 to 23.27) | 7.07 (1.87 to 12.27) | 11.27 (5.85 to 16.69) |
| Entire treatment period | 15.30 (10.61 to 20.00) | 15.59 (10.93 to 20.25) | 14.79 (10.07 to 19.50) | 18.17 (13.49 to 22.86) | 7.98 (3.25 to 12.72) | 12.39 (7.45 to 17.32) |
Evaluate the change from baseline in average use of rescue medication (number of puffs/day) during the inter-visit periods and the entire treatment period. Results are shown as number of puffs/day; a decrease (implies improvement) from baseline in average use of rescue medication. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3 (Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0);
| Number of puffs/day | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Inter-visit period 1 | -0.72 (-0.90 to -0.55) | -0.58 (-0.75 to -0.41) | -0.53 (-0.70 to -0.35) | -0.71 (-0.89 to -0.54) | -0.30 (-0.47 to -0.12) | -0.52 (-0.70 to -0.34) |
| Inter-visit period 2 | -0.59 (-0.78 to -0.39) | -0.50 (-0.69 to -0.30) | -0.51 (-0.71 to -0.31) | -0.69 (-0.89 to -0.50) | -0.17 (-0.37 to 0.03) | -0.40 (-0.61 to -0.19) |
| Entire treatment period | -0.66 (-0.83 to -0.48) | -0.54 (-0.71 to -0.37) | -0.52 (-0.70 to -0.34) | -0.70 (-0.88 to -0.53) | -0.23 (-0.41 to -0.06) | -0.46 (-0.64 to -0.28) |
Change from baseline in average EXACT-Respiratory Symptom (E-RS) total score during inter-visit periods and the entire treatment period E-RS in COPD uses 11 respiratory symptom items from the 14-item EXAcerbations of COPD tool (EXACT). E-RS total score quantifies respiratory symptom severity on a scale ranging from 0 to 40. Higher E-RS total scores indicate more severe symptoms and a declining total score indicates health improvement. E-RS questionnaire was completed by the patient each evening (e-diary). Definitions: For details on baseline, inter-visit periods, and the entire treatment period, please refer to outcome measure #15.
| score on a scale | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| Inter-visit period 1 | -1.681 (-2.236 to -1.127) | -1.539 (-2.087 to -0.990) | -1.941 (-2.495 to -1.388) | -1.663 (-2.215 to -1.111) | -0.714 (-1.272 to -0.157) | -1.280 (-1.862 to -0.698) |
| Inter-visit period 2 | -2.030 (-2.694 to -1.365) | -1.840 (-2.499 to -1.180) | -2.147 (-2.818 to -1.475) | -2.077 (-2.737 to -1.417) | -0.681 (-1.353 to -0.009) | -1.505 (-2.206 to -0.803) |
| Entire treatment period | -1.855 (-2.433 to -1.278) | -1.689 (-2.262 to -1.116) | -2.044 (-2.624 to -1.464) | -1.870 (-2.445 to -1.295) | -0.698 (-1.280 to -0.115) | -1.393 (-2.001 to -0.784) |
Vital signs -- Systolic blood pressure (SBP), Diastolic blood pressure (DBP) were measured at prespecified times, using a 12-Lead single ECGs were recorded at all study visits (pre-dose at V1 (Week -2) and V3 (Week 3), as well as at pre-dose and 1.5 hours post-dose at Visit 2 (Week 0) and Visit 4 (Week 6). Results are shown by treatment group, as change from baseline (in mmHg) for representative timepoints. Definitions: Baseline=Values recorded pre-dose (Visit 2, Week 0); Day 1=Day of the first dose of randomized study drug (Visit 2, Week 0);
| mmHg | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| SBP, Day 1, 30 min post dose | -1.4 (-31 to 25) | -0.4 (-24 to 24) | -2.0 (-31 to 24) | -1.9 (-32 to 34) | -0.9 (-25 to 26) | -1.2 (-32 to 30) |
| DBP, Day 1, 30 min post dose | -0.7 (-21 to 14) | -0.6 (-15 to 15) | -2.1 (-20 to 11) | -1.4 (-28 to 17) | -0.8 (-15 to 12) | 0.1 (-27 to 22) |
| SBP, Day 1, 1,5 h post dose | 0.3 (-33 to 24) | -1.1 (-29 to 36) | -0.6 (-33 to 24) | -1.8 (-34 to 22) | 0.2 (-25 to 33) | -1.5 (-30 to 34) |
| DBP, Day 1, 1,5 h post dose | -0.7 (-20 to 17) | -1.8 (-22 to 20) | -1.7 (-23 to 13) | -1.6 (-31 to 17) | -1.7 (-18 to 14) | -1.5 (-23 to 23) |
| SBP, Day 1, 11 h post dose | 1.1 (-27 to 34) | 2.0 (-25 to 39) | -0.0 (-34 to 34) | 1.7 (-26 to 39) | 1.9 (-35 to 56) | 0.9 (-25 to 48) |
| DBP, Day 1, 11 h post dose | -0.9 (-20 to 17) | 0.3 (-18 to 21) | -1.6 (-27 to 17) | -1.4 (-18 to 20) | -1.0 (-25 to 22) | -1.2 (-19 to 27) |
| SBP, Week 6, pre-dose | 0.4 (-34 to 31) | 0.8 (-50 to 34) | 0.4 (-27 to 47) | -1.0 (-36 to 47) | 1.6 (-32 to 46) | 1.3 (-33 to 63) |
| DBP, Week 6, pre-dose | 0.4 (-32 to 25) | 0.5 (-23 to 21) | -0.3 (-16 to 18) | -1.0 (-28 to 25) | 0.0 (-26 to 18) | -0.2 (-30 to 20) |
| SBP, Week 6, 30 min post dose | -1.6 (-35 to 27) | -0.9 (-62 to 39) | -0.5 (-34 to 42) | -2.5 (-41 to 35) | 0.5 (-30 to 42) | 0.1 (-35 to 54) |
| DBP, Week 6, 30 min post dose | -0.7 (-24 to 21) | -0.9 (-28 to 19) | -1.5 (-24 to 19) | -2.0 (-25 to 22) | -0.8 (-24 to 24) | -1.2 (-26 to 24) |
| SBP, Week 6, 1,5 h post dose | -1.3 (-32 to 31) | -0.6 (-31 to 36) | -0.5 (-34 to 47) | -2.3 (-42 to 40) | 0.1 (-34 to 49) | 0.5 (-34 to 67) |
| DBP, Week 6, 1,5 h post dose | -1.0 (-28 to 21) | -2.7 (-28 to 16) | -2.0 (-21 to 17) | -2.3 (-30 to 22) | -1.1 (-31 to 19) | -0.6 (-28 to 33) |
| SBP, Week 6, 11 h post dose | 0.2 (-38 to 36) | 1.5 (-26 to 36) | 0.5 (-31 to 53) | 2.2 (-37 to 53) | 3.2 (-25 to 66) | 2.0 (-26 to 45) |
| DBP, Week 6, 11 h post dose | -0.9 (-24 to 21) | -2.0 (-27 to 19) | -2.3 (-25 to 25) | -1.4 (-27 to 21) | -1.0 (-27 to 20) | -0.7 (-17 to 21) |
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Heart rate (HR) Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5m, +55m, and at +2.5 h.
| bpm | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| HR, Day 1, 5 min post dose | -8.85 (-57.3 to 16.3) | -6.62 (-53.7 to 22.3) | -7.78 (-44.0 to 14.3) | -7.64 (-41.3 to 19.0) | -4.84 (-39.7 to 31.7) | -5.54 (-34.3 to 24.3) |
| HR, Day 1, 55 min post dose | -7.19 (-45.7 to 12.0) | -8.29 (-33.3 to 10.3) | -8.28 (-40.0 to 27.7) | -9.59 (-74.0 to 17.3) | -7.44 (-49.3 to 36.3) | -7.19 (-41.3 to 37.7) |
| HR, Day 1, 2.5 h post dose | -7.57 (-51.7 to 19.3) | -6.75 (-51.0 to 16.7) | -9.20 (-46.7 to 26.7) | -7.46 (-94.7 to 21.0) | -6.12 (-45.7 to 30.3) | -8.96 (-40.0 to 18.0) |
| HR, Day before Week 6, 5 min post dose | -1.72 (-56.3 to 34.3) | -1.06 (-47.0 to 44.3) | -1.61 (-37.0 to 30.3) | -1.85 (-31.3 to 36.0) | 3.92 (-31.3 to 47.0) | 1.70 (-28.7 to 25.7) |
| HR, Day before Week 6, 55 min post dose | -1.52 (-40.7 to 33.0) | 0.41 (-30.0 to 33.0) | -1.10 (-37.3 to 49.3) | -1.40 (-77.7 to 25.0) | 1.12 (-41.3 to 44.2) | 1.22 (-25.3 to 36.7) |
| HR, Day before Week 6, 2.5 h post dose | -2.30 (-48.0 to 22.3) | -0.01 (-58.3 to 44.3) | -1.13 (-39.3 to 26.3) | -0.73 (-42.0 to 39.7) | 2.49 (-35.7 to 43.7) | -1.47 (-34.7 to 44.0) |
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - PR Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
| msec | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| PR Interval, Day 1, 5 min post dose | 7.24 (-23.0 to 54.7) | 6.53 (-17.3 to 48.3) | 6.08 (-36.0 to 37.3) | 6.71 (-14.3 to 41.7) | 3.06 (-20.7 to 33.7) | 4.90 (-18.3 to 30.7) |
| PR Interval, Day 1, 55 min post dose | 7.20 (-23.0 to 59.7) | 6.89 (-24.3 to 120.7) | 8.21 (-26.7 to 42.3) | 6.77 (-20.0 to 49.3) | 4.38 (-35.7 to 36.0) | 4.77 (-32.7 to 40.0) |
| PR Interval, Day 1, 2.5 h post dose | 8.48 (-20.3 to 77.7) | 9.38 (-37.0 to 131.3) | 7.58 (-18.7 to 91.3) | 6.16 (-22.0 to 47.3) | 5.84 (-27.0 to 38.7) | 4.25 (-36.7 to 40.7) |
| PR Interval, Day before Week 6, 5 min post dose | 0.44 (-27.7 to 39.3) | 1.36 (-30.0 to 59.0) | -0.11 (-54.3 to 26.7) | 3.88 (-33.3 to 204.0) | -1.36 (-48.3 to 31.7) | 0.82 (-23.3 to 37.2) |
| PR Interval, Day before Week 6, 55 min post dose | 0.88 (-47.3 to 32.3) | 2.37 (-53.7 to 38.7) | 1.91 (-76.3 to 37.7) | 0.82 (-33.3 to 50.0) | -1.13 (-46.0 to 48.3) | -1.66 (-48.0 to 25.0) |
| PR Interval, Day before Week 6, 2.5 h post dose | 2.50 (-38.7 to 40.0) | 3.01 (-54.7 to 76.0) | 0.16 (-59.0 to 81.0) | 0.84 (-30.0 to 61.7) | -1.22 (-59.0 to 47.7) | -1.94 (-47.0 to 55.3) |
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - QRS Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
| msec | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| QRS Interval, Day 1, 5 min post dose | 1.18 (-15.0 to 14.7) | 0.05 (-17.7 to 16.7) | 1.50 (-12.0 to 17.7) | 1.99 (-6.0 to 16.7) | 0.45 (-13.0 to 20.3) | 1.50 (-14.0 to 13.0) |
| QRS Interval, Day 1, 55 min post dose | 0.97 (-16.3 to 15.0) | 1.19 (-18.0 to 31.0) | 1.21 (-14.7 to 20.0) | 1.56 (-11.0 to 14.7) | 0.14 (-13.7 to 13.7) | 1.70 (-13.3 to 16.3) |
| QRS Interval, Day 1, 2.5 h post dose | 1.38 (-14.0 to 15.0) | 2.40 (-15.3 to 23.7) | 1.80 (-23.0 to 17.3) | 1.50 (-17.8 to 27.3) | 0.64 (-10.3 to 20.8) | 0.86 (-20.7 to 18.7) |
| QRS Interval, Day before Week 6, 5 min post dose | 0.61 (-23.3 to 34.0) | -1.76 (-76.0 to 17.3) | 0.43 (-15.0 to 13.3) | 2.00 (-8.7 to 67.3) | 0.45 (-22.3 to 44.3) | 0.69 (-17.0 to 17.5) |
| QRS Interval, Day before Week 6, 55 min post dose | 1.12 (-10.7 to 29.3) | -0.09 (-76.7 to 30.0) | 0.85 (-18.3 to 13.7) | 2.38 (-10.7 to 62.3) | 0.77 (-16.0 to 53.7) | 0.42 (-20.3 to 17.7) |
| QRS Interval, Day before Week 6, 2.5 h post dose | 1.49 (-14.0 to 40.0) | 0.74 (-73.0 to 25.0) | 0.30 (-18.3 to 24.0) | 2.18 (-18.2 to 59.3) | 1.14 (-14.7 to 43.7) | 1.35 (-15.7 to 27.0) |
Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Fridericia-corrected QT interval (QTcF). Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
| msec | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| QTcF, Day 1, 5 min post dose | 3.62 (-38.0 to 39.7) | 5.37 (-48.7 to 55.7) | 6.81 (-34.0 to 39.7) | 6.25 (-30.3 to 52.7) | 3.59 (-33.3 to 50.3) | 5.56 (-21.7 to 53.3) |
| QTcF, Day 1, 55 min post dose | 8.37 (-35.3 to 47.0) | 5.41 (-52.3 to 45.0) | 6.72 (-43.7 to 40.7) | 9.90 (-20.3 to 67.7) | 6.04 (-34.7 to 61.3) | 5.43 (-24.7 to 42.5) |
| QTcF, Day 1, 2.5 h post dose | 7.15 (-31.3 to 38.0) | 8.65 (-25.3 to 58.0) | 7.20 (-22.3 to 36.3) | 5.45 (-27.7 to 100.0) | 4.81 (-75.7 to 61.3) | 6.77 (-38.3 to 48.3) |
| QTcF, Day before Week 6, 5 min post dose | 1.61 (-44.3 to 35.7) | 1.14 (-70.7 to 76.3) | -0.60 (-30.3 to 30.0) | 1.67 (-26.3 to 57.2) | -3.56 (-40.0 to 26.7) | 1.41 (-26.7 to 58.0) |
| QTcF, Day before Week 6, 55 min post dose | 2.38 (-28.7 to 45.0) | 0.09 (-45.0 to 30.0) | 1.41 (-65.0 to 40.7) | 4.15 (-32.7 to 47.3) | 1.02 (-22.7 to 32.7) | 3.19 (-30.3 to 63.5) |
| QTcF, Day before Week 6, 2.5 h post dose | 4.13 (-32.7 to 40.7) | 0.85 (-64.0 to 51.7) | -0.97 (-55.3 to 48.3) | 1.73 (-44.0 to 49.3) | 0.14 (-31.0 to 33.7) | 2.50 (-29.3 to 44.0) |
24-hour Holter ECG - Prolonged QTcF - Male subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
| Participants | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| QTcF, Day -1, 5 min — Actual value > 450 msec | 1 | 0 | 0 | 1 | 2 | 1 |
| QTcF, Day -1, 5 min — Actual value > 480 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 5 min — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 5 min — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 62 | 55 | 54 | 57 | 67 | 65 |
| QTcF, Day -1, 55 min — Actual value > 450 msec | 1 | 1 | 1 | 3 | 1 | 3 |
| QTcF, Day -1, 55 min — Actual value > 480 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 55 min — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 55 min — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 62 | 54 | 53 | 55 | 68 | 63 |
| QTcF, Day -1, 2.5 h — Actual value > 450 msec | 1 | 1 | 0 | 2 | 2 | 0 |
| QTcF, Day -1, 2.5 h — Actual value > 480 msec | 0 | 0 | 0 | 0 | 1 | 0 |
| QTcF, Day -1, 2.5 h — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 2.5 h — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 62 | 54 | 54 | 56 | 66 | 66 |
| QTcF, Any post dose time point — Actual value > 450 msec | 3 | 4 | 6 | 4 | 2 | 5 |
| QTcF, Any post dose time point — Actual value > 480 msec | 1 | 0 | 1 | 0 | 0 | 3 |
| QTcF, Any post dose time point — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Any post dose time point — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 59 | 51 | 47 | 54 | 67 | 58 |
| QTcF, Day 1, 5 min post dose — Actual value > 450 msec | 2 | 2 | 3 | 3 | 1 | 4 |
| QTcF, Day 1, 5 min post dose — Actual value > 480 msec | 1 | 0 | 0 | 0 | 0 | 1 |
| QTcF, Day 1, 5 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 5 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 60 | 53 | 51 | 55 | 68 | 61 |
| QTcF, Day 1, 55 min post dose — Actual value > 450 msec | 2 | 2 | 3 | 3 | 1 | 4 |
| QTcF, Day 1, 55 min post dose — Actual value > 480 msec | 1 | 0 | 1 | 0 | 0 | 1 |
| QTcF, Day 1, 55 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 55 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 60 | 53 | 50 | 55 | 68 | 61 |
| QTcF, Day 1, 2.5 h post dose — Actual value > 450 msec | 3 | 3 | 3 | 2 | 1 | 4 |
| QTcF, Day 1, 2.5 h post dose — Actual value > 480 msec | 1 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 2.5 h post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 2.5 h post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 59 | 52 | 51 | 56 | 68 | 62 |
| QTcF, Day before Week 6, 5 min post dose — Actual value > 450 msec | 3 | 1 | 0 | 3 | 0 | 2 |
| QTcF, Day before Week 6, 5 min post dose — Actual value > 480 msec | 0 | 0 | 0 | 0 | 0 | 1 |
| QTcF, Day before Week 6, 5 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 5 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 60 | 54 | 54 | 55 | 69 | 63 |
| QTcF, Day before Week 6, 55 min post dose — Actual value > 450 msec | 2 | 2 | 2 | 2 | 0 | 3 |
| QTcF, Day before Week 6, 55 min post dose — Actual value > 480 msec | 0 | 0 | 0 | 0 | 0 | 1 |
| QTcF, Day before Week 6, 55 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 55 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 61 | 53 | 52 | 56 | 69 | 62 |
| QTcF, Day before Week 6, 2.5 h post dose — Actual value > 450 msec | 1 | 1 | 0 | 1 | 0 | 3 |
| QTcF, Day before Week 6, 2.5 h post dose — Actual value > 480 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 2.5 h post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 2.5 h post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec) | 62 | 54 | 54 | 57 | 69 | 63 |
24-hour Holter ECG - Prolonged QTcF - Female subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.
| Participants | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| QTcF, Day -1, 5 min — Actual value > 470 msec | 0 | 1 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 5 min — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 5 min — No prolongation (> 470 msec or > 500 msec) | 58 | 67 | 67 | 65 | 52 | 57 |
| QTcF, Day -1, 55 min — Actual value > 470 msec | 1 | 2 | 0 | 1 | 0 | 0 |
| QTcF, Day -1, 55 min — Actual value > 500 msec | 0 | 2 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 55 min — No prolongation (> 470 msec or > 500 msec) | 57 | 64 | 67 | 64 | 52 | 57 |
| QTcF, Day -1, 2.5 h — Actual value > 470 msec | 1 | 2 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 2.5 h — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day -1, 2.5 h — No prolongation (> 470 msec or > 500 msec) | 57 | 66 | 67 | 65 | 52 | 57 |
| QTcF, Any post dose time point — Actual value > 470 msec | 3 | 3 | 0 | 1 | 0 | 1 |
| QTcF, Any post dose time point — Actual value > 500 msec | 0 | 1 | 0 | 0 | 0 | 0 |
| QTcF, Any post dose time point — No prolongation (> 470 msec or > 500 msec) | 55 | 64 | 67 | 64 | 52 | 56 |
| QTcF, Day 1, 5 min post dose — Actual value > 470 msec | 1 | 2 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 5 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 5 min post dose — No prolongation (> 470 msec or > 500 msec) | 57 | 66 | 67 | 65 | 52 | 57 |
| QTcF, Day 1, 55 min post dose — Actual value > 470 msec | 2 | 3 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 55 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 55 min post dose — No prolongation (> 470 msec or > 500 msec) | 56 | 65 | 67 | 65 | 52 | 57 |
| QTcF, Day 1, 2.5 h post dose — Actual value > 470 msec | 1 | 2 | 0 | 0 | 0 | 1 |
| QTcF, Day 1, 2.5 h post dose — Actual value > 500 msec | 0 | 1 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 2.5 h post dose — No prolongation (> 470 msec or > 500 msec) | 57 | 65 | 67 | 65 | 52 | 56 |
| QTcF, Day before Week 6, 5 min post dose — Actual value > 470 msec | 1 | 2 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 5 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 5 min post dose — No prolongation (> 470 msec or > 500 msec) | 57 | 66 | 67 | 65 | 52 | 57 |
| QTcF, Day before Week 6, 55 min post dose — Actual value > 470 msec | 0 | 2 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 55 min post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 55 min post dose — No prolongation (> 470 msec or > 500 msec) | 58 | 66 | 67 | 65 | 52 | 57 |
| QTcF, Day before Week 6, 2.5 h post dose — Actual value > 470 msec | 0 | 1 | 0 | 1 | 0 | 0 |
| QTcF, Day before Week 6, 2.5 h post dose — Actual value > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 2.5 h post dose — No prolongation (> 470 msec or > 500 msec) | 58 | 67 | 67 | 64 | 52 | 57 |
24-hour Holter ECG - Prolonged QTcF - Change from baseline. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h. Results are presented as the number of subjects who had a change from baseline in QTcF of: \> 30 msec, \> 60 msec, and no prolongation (by \> 30 msec or \> 60 msec).
| Participants | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| QTcF, Any post dose time point — Change from baseline: > 30 msec | 19 | 20 | 21 | 20 | 16 | 18 |
| QTcF, Any post dose time point — Change from baseline: > 60 msec | 0 | 1 | 0 | 2 | 2 | 1 |
| QTcF, Any post dose time point — No change from baseline (> 30 msec or > 60 msec) | 102 | 102 | 100 | 101 | 103 | 104 |
| QTcF, Day 1, 5 min post dose — Change from baseline: > 30 msec | 2 | 4 | 9 | 2 | 3 | 4 |
| QTcF, Day 1, 5 min post dose — Change from baseline: > 60 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day 1, 5 min post dose — No change from baseline (> 30 msec or > 60 msec) | 119 | 119 | 112 | 121 | 118 | 119 |
| QTcF, Day 1, 55 min post dose — Change from baseline: > 30 msec | 8 | 4 | 5 | 6 | 4 | 5 |
| QTcF, Day 1, 55 min post dose — Change from baseline: > 60 msec | 0 | 0 | 0 | 1 | 1 | 0 |
| QTcF, Day 1, 55 min post dose — No change from baseline (> 30 msec or > 60 msec) | 113 | 119 | 116 | 116 | 116 | 118 |
| QTcF, Day 1, 2.5 h post dose — Change from baseline: > 30 msec | 5 | 12 | 6 | 5 | 6 | 8 |
| QTcF, Day 1, 2.5 h post dose — Change from baseline: > 60 msec | 0 | 0 | 0 | 1 | 1 | 0 |
| QTcF, Day 1, 2.5 h post dose — No change from baseline (> 30 msec or > 60 msec) | 116 | 111 | 115 | 117 | 114 | 115 |
| QTcF, Day before Week 6, 5 min post dose — Change from baseline: > 30 msec | 5 | 3 | 0 | 3 | 0 | 3 |
| QTcF, Day before Week 6, 5 min post dose — Change from baseline: > 60 msec | 0 | 1 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 5 min post dose — No change from baseline (> 30 msec or > 60 msec) | 116 | 119 | 121 | 120 | 121 | 120 |
| QTcF, Day before Week 6, 55 min post dose — Change from baseline: > 30 msec | 5 | 0 | 7 | 7 | 3 | 4 |
| QTcF, Day before Week 6, 55 min post dose — Change from baseline: > 60 msec | 0 | 0 | 0 | 0 | 0 | 1 |
| QTcF, Day before Week 6, 55 min post dose — No change from baseline (> 30 msec or > 60 msec) | 116 | 123 | 114 | 116 | 118 | 118 |
| QTcF, Day before Week 6, 2.5 h post dose — Change from baseline: > 30 msec | 6 | 6 | 3 | 6 | 3 | 7 |
| QTcF, Day before Week 6, 2.5 h post dose — Change from baseline: > 60 msec | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF, Day before Week 6, 2.5 h post dose — No change from baseline (> 30 msec or > 60 msec) | 115 | 117 | 118 | 117 | 118 | 116 |
Collected over From the first intake of study medication (visit 2, Week 0) until study completion (Visit 4, week 6) or discontinuation.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/121 (0%) | 2/121 (1.7%) | 16/121 (13.2%) |
| Treatment B | 0/123 (0%) | 5/123 (4.1%) | 14/123 (11.4%) |
| Treatment C | 0/121 (0%) | 1/121 (0.8%) | 8/121 (6.6%) |
| Treatment D | 0/123 (0%) | 1/123 (0.8%) | 15/123 (12.2%) |
| Treatment E | 0/121 (0%) | 1/121 (0.8%) | 11/121 (9.1%) |
| Treatment F | 0/123 (0%) | 1/123 (0.8%) | 9/123 (7.3%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/121 | 0/123 | 0/121 | 0/123 | 0/121 | 0/123 |
| Prostate cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 | 0/123 | 0/121 | 0/123 | 0/121 | 0/123 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/121 | 1/123 | 1/121 | 0/123 | 0/121 | 0/123 |
| HypertensionVascular disorders | 0/121 | 0/123 | 0/121 | 0/123 | 1/121 | 0/123 |
| InfluenzaInfections and infestations | 0/121 | 0/123 | 0/121 | 1/123 | 0/121 | 0/123 |
| Femur fractureInjury, poisoning and procedural complications | 0/121 | 1/123 | 0/121 | 0/123 | 0/121 | 0/123 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/121 | 1/123 | 0/121 | 0/123 | 0/121 | 0/123 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/121 | 0/123 | 0/121 | 0/123 | 0/121 | 1/123 |
| Cerebrovascular accidentNervous system disorders | 0/121 | 1/123 | 0/121 | 0/123 | 0/121 | 0/123 |
| NephrolithiasisRenal and urinary disorders | 0/121 | 1/123 | 0/121 | 0/123 | 0/121 | 0/123 |
| Event | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 5/121 | 2/123 | 1/121 | 3/123 | 2/121 | 0/123 |
| Upper respiratory tract infectionInfections and infestations | 4/121 | 2/123 | 2/121 | 5/123 | 2/121 | 3/123 |
| Viral upper respiratory tract infectionInfections and infestations | 0/121 | 5/123 | 1/121 | 1/123 | 3/121 | 0/123 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/121 | 0/123 | 3/121 | 4/123 | 4/121 | 4/123 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/121 | 1/123 | 0/121 | 1/123 | 0/121 | 2/123 |
| BronchitisInfections and infestations | 1/121 | 4/123 | 1/121 | 1/123 | 0/121 | 0/123 |
Eligible patients male or female, aged ≥ 40 years with a diagnosis of COPD at least 12 months before the screening visit, who were current smokers or ex-smokers who had quit smoking at least 6 months prior to the screening visit, with a smoking history of at least 10 pack-years. Study inclusion and exclusion criteria are presented in the study protocol section.
| Age, Continuous(years) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| Mean | 64.1 ± 9.13 | 65.3 ± 9.10 | 65.3 ± 8.16 | 64.9 ± 9.11 | 64.9 ± 9.25 | 63.8 ± 9.55 | 64.7 ± 9.05 |
| Age, Customized(Participants) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| < 65 years | 59 | 53 | 56 | 62 | 60 | 62 | 352 |
| 65-84 years | 60 | 68 | 65 | 60 | 58 | 59 | 370 |
| > 85 years | 2 | 2 | 0 | 1 | 3 | 2 | 10 |
| Sex: Female, Male(Participants) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| Female | 58 | 68 | 67 | 65 | 52 | 57 | 367 |
| Male | 63 | 55 | 54 | 58 | 69 | 66 | 365 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 12 | 11 | 5 | 7 | 51 |
| Not Hispanic or Latino | 114 | 114 | 109 | 112 | 115 | 116 | 680 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Asian | 1 | 0 | 0 | 0 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 10 | 10 | 14 | 12 | 10 | 69 |
| White | 107 | 110 | 107 | 108 | 104 | 110 | 646 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 4 | 1 | 1 | 2 | 11 |
| Region of Enrollment(Participants) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| United States | 121 | 123 | 121 | 123 | 121 | 123 | 732 |
| Weight(kg) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| Mean | 81.81 ± 20.64 | 83.82 ± 19.33 | 82.12 ± 22.70 | 84.23 ± 22.41 | 84.43 ± 21.82 | 80.67 ± 17.40 | 82.85 ± 20.77 |
| Height(cm) | Treatment A | Treatment B | Treatment C | Treatment D | Treatment E | Treatment F | Total |
|---|---|---|---|---|---|---|---|
| Mean | 168.95 ± 8.76 | 169.38 ± 9.74 | 169.21 ± 9.67 | 168.17 ± 9.57 | 169.34 ± 9.56 | 169.53 ± 9.67 | 169.10 ± 9.48 |
12 further baseline measures are reported on the registry.
Showing the first 100 of 112 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in May 2018, 9 months.
Results were first posted in Jun 2021, 3 years after primary completion. A results delay was requested in May 2019.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 9 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →